ZURICH. Switzerland's pharmaceutical industry is pressing the federal government to shorten the time it takes for new medicines to reach Swiss patients, arguing that the country is losing ground to regulators it once outpaced. The campaign reflects a growing anxiety in Basel's pharma cluster that a reputation for scientific excellence means little if approvals arrive months after those in Washington or Brussels.
Industry figures show the median approval time for novel drugs at the Swiss regulator now runs to roughly 480 days from filing, against about 330 days at the US Food and Drug Administration and 430 at the European Medicines Agency. For a therapy selling CHF 3 million a day globally, each month of delay in a market of nine million people is commercially trivial; the cumulative signal, executives argue, is not.
The lag is a recent phenomenon. For decades Swissmedic enjoyed a reputation for speed and rigour, and its decisions carried weight well beyond the country's borders. A surge in complex biologics, gene therapies and combination products has since strained a workforce that has not grown at the same pace, while pandemic-era backlogs proved slower to clear than expected. Staff numbers have risen since, but the recruitment of specialist reviewers takes years rather than months.
The pressure is felt most acutely by the smaller biotech firms clustered around Basel and the Geneva lake arc, which plan launches around regulatory milestones and cannot afford staggered filings. Larger groups can absorb delay, but even they have begun to sequence Switzerland behind larger markets in filing strategies, a quiet reordering that alarms the industry's Swiss leadership.
Patients stand to gain most from faster approvals, particularly in oncology, where months can matter. Health insurers are warier: quicker access can mean earlier exposure to high launch prices before cost-effectiveness is established. Generic manufacturers, a growing employer in their own right, favour faster procedures too, since delayed approvals for originator drugs cascade into delayed opportunities for their own products.
The industry associations have proposed remedies that go beyond money. Interpharma has suggested expanded reliance on trusted foreign regulators, project-based hiring for specialist reviewers and fees tied to performance targets. Patient groups have joined the chorus, an alignment that strengthens the industry's hand in Bern.
“Switzerland should be the first wave of a launch, not the afterthought,” said a spokesperson for Interpharma. “Every month of delay is a message to boardrooms abroad that this market can wait.”
Bern is listening. The Federal Council has commissioned a review of Swissmedic's mandate and funding, and a cross-party group in parliament has tabled motions calling for approval timelines to be reported annually against international benchmarks. The health ministry has signalled openness to reliance pathways, though officials stress that safety standards are not negotiable.
The review is due to report in the spring, with a consultation on legislative changes to follow. In the meantime, Swissmedic has begun publishing monthly backlog figures and has recruited reviewers from industry, a move that has revived an old debate about revolving doors. Industry observers say the backlog figures will be the first measure by which the regulator's recovery is judged. The first real test will be next year's cohort of cell and gene therapy filings.
The argument extends beyond pharmaceuticals. How Switzerland regulates complex products, from medical devices to artificial intelligence in diagnostics, will shape whether the life sciences cluster keeps expanding or gradually shifts decision-making abroad. Approval speed has become a proxy for the country's appetite for regulated innovation.
For an industry that contributes more than a third of Swiss goods exports, the stakes justify the lobbying. The likely outcome is incremental rather than revolutionary: more staff, smarter reliance and firmer targets. The companies, for their part, have made clear that filing sequences for the coming wave of therapies are being decided now. Whether that is enough to keep Basel at the front of the launch queue will be visible in the filing calendars of the next two years.